An experimental human papillomavirus vaccine made by Merck could offer a boost to the vaccine market, but the company will have to use effective marketing efforts to ensure uptake, according to a new study.
While rates of human papillomavirus infection among girls ages 14 years to 19 years have dropped by half since the Centers for Disease Control and Prevention started recommending routine vaccination against it seven years ago, rates of vaccination have not increased, the agency said.
As pharmacies become increasingly involved in flu shots, retail-based clinics are expanding into other areas of vaccination — such as vaccines to help protect against human papillomavirus, meningitis and pneumonia — to further meet the healthcare needs of patients.
At the beginning of the year, a major global controversy was settled when it turned out that a study published in The Lancet in 1998 linking the measles-mumps-rubella vaccine to autism in children turned out to be a whopper of a fraud.
Health experts have expressed fear that Republican presidential candidate Michele Bachmann's comments about the human papillomavirus vaccine could set back progress in vaccinations, according to published reports.
Take Care Health Systems announced Thursday that through April 30, the retail clinic operator will be offering sports and camp physicals for $35. The physicals, regularly $60, are administered by board-certified nurse practitioners and physician assistants at select Walgreens locations.
Merck on Wednesday announced that the Food and Drug Administration has approved Gardasil [human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant] for the prevention of anal cancer in males and females 9 to 26 years of age.